Pharming Group (NASDAQ:PHAR) to Post Q3 2024 Earnings of $0.11 Per Share, HC Wainwright Forecasts

Pharming Group (NASDAQ:PHAR) – Investment analysts at HC Wainwright raised their Q3 2024 earnings estimates for Pharming Group in a research note issued on Thursday, August 1st. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of $0.11 per share for the quarter, up from their previous estimate of $0.10. HC Wainwright has a “Buy” rating and a $37.00 price target on the stock. The consensus estimate for Pharming Group’s current full-year earnings is ($0.03) per share. HC Wainwright also issued estimates for Pharming Group’s FY2024 earnings at $0.00 EPS, FY2025 earnings at $0.65 EPS and FY2026 earnings at $1.35 EPS.

Pharming Group (NASDAQ:PHAR) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($0.01) earnings per share (EPS) for the quarter. Pharming Group had a negative net margin of 4.65% and a negative return on equity of 5.75%. The business had revenue of $74.09 million for the quarter, compared to the consensus estimate of $71.95 million. During the same period in the prior year, the business posted $0.02 EPS.

Pharming Group Trading Up 6.7 %

Shares of NASDAQ PHAR opened at $8.09 on Monday. The business has a 50-day moving average of $8.33 and a 200-day moving average of $9.92. The firm has a market capitalization of $544.81 million, a price-to-earnings ratio of -50.56 and a beta of 0.15. Pharming Group has a 12 month low of $6.65 and a 12 month high of $16.71.

Hedge Funds Weigh In On Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its position in shares of Pharming Group (NASDAQ:PHAR) by 32.3% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 23,435 shares of the company’s stock after buying an additional 5,725 shares during the period. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 as of its most recent SEC filing. 0.03% of the stock is owned by institutional investors.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.